Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells $76,923.84 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the transaction, the director now owns 7,077,560 shares in the company, valued at $47,561,203.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.67, for a total value of $76,351.49.
• On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.22, for a total value of $71,200.34.
• On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48.
• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.27, for a total transaction of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.12, for a total value of $81,502.64.
• On Tuesday, August 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.82, for a total transaction of $78,068.54.

Recursion Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ RXRX opened at $6.40 on Friday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -3.95 and a beta of 0.81. The business’s 50 day moving average price is $6.63 and its 200-day moving average price is $7.64.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.38) EPS. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Needham & Company LLC dropped their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Jefferies Financial Group decreased their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.40.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently added to or reduced their stakes in RXRX. Green Alpha Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 2.9% during the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after acquiring an additional 1,800 shares during the period. Interchange Capital Partners LLC raised its position in Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after purchasing an additional 2,349 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the period. Victory Capital Management Inc. increased its stake in shares of Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the period. Finally, Marathon Capital Management raised its holdings in shares of Recursion Pharmaceuticals by 1.6% in the second quarter. Marathon Capital Management now owns 175,220 shares of the company’s stock valued at $1,314,000 after acquiring an additional 2,675 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.